semaglutide – Page 4 – Talk Bio

Actionable Insights Powered by AI

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

11 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

Novo Nordisk’s Wegovy Shows Superior Improvement in Liver Fibrosis and MASH Resolution in Phase III ESSENCE Trial

1 year ago talkbio0Tagged Fibrosis, Liver, MASH, Nordisk, Phase III ESSENCE trial, Rezdiffra, semaglutide, Wegovy

Novo Nordisk, Wegovy, semaglutide, MASH, liver fibrosis, Phase III ESSENCE trial, Madrigal Pharmaceuticals, Rezdiffra

FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy

1 year ago talkbio0Tagged Diabetes, Drug Shortage, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment

Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns

1 year ago talkbio0Tagged concerns, Diabetes, Glucagon-Like Peptide 1, Nordisk, Pharmacy facility, Safety, semaglutide, United States Food and Drug Administration, Weight-Loss Agents

Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments

Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial

1 year ago talkbio0Tagged agonists, Body mass index procedure, Glucagon-Like Peptide 1, liraglutide, Nordisk, Obesity, Pediatric brand name, Phase 3 trial, semaglutide

GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.

Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis

1 year ago talkbio0Tagged Analysis of substances, Cardiovascular system, Diabetes, Nordisk, Obesity, outcomes, semaglutide

Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis

Semaglutide and Mental Health: A Complex Relationship

1 year ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, ideation, mental health, semaglutide, Suicidal

semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes

Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges

1 year ago talkbio0Tagged Approved, China, competition, Expiration, function, Legal patent, Nordisk, Obesity, pharmaceutical market, semaglutide, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market

Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection

1 year ago talkbio0Tagged Clinical Research, COMBINE-1, File (record), Icodec, IcoSema, Insulin, Nordisk, once-weekly, regulatory approval, semaglutide, United States Food and Drug Administration

Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval

Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns

1 year ago talkbio0Tagged Icodec, IcoSema, Insulin, Nordisk, once-weekly, Rejection (Psychology), semaglutide, United States Food and Drug Administration

Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema